Takayasu Arteritis News and Research

RSS

RINVOQ® (upadacitinib) Approved by European Commission as an Oral Treatment for Adults with Active Non-Radiographic Axial Spondyloarthritis

With this approval, RINVOQ® is the first and only Janus Kinase inhibitor approved to treat patients across the spectrum of axial spondyloarthritis (nr-axSpA and ankylosing spondylitis) in the EU.

From AbbVie 29 Jul 2022

Potential new diagnostic marker for ulcerative colitis discovered

An international research collaboration has discovered a potential new diagnostic marker for ulcerative colitis in a trans-ethnic analysis of Japanese and white patients.

10 Feb 2022

Three new guidelines released for treatment and management of systemic vasculitis

The American College of Rheumatology, in partnership with the Vasculitis Foundation (VF), released three new guidelines for the treatment and management of systemic vasculitis.

9 Jul 2021

Study uncovers genetic risks of Takayasu arteritis

In a paper published today in the American Journal of Human Genetics, a group of international collaborators led by researchers from the University of Pittsburgh School of Medicine identified new genetic associations that can predict individual susceptibility to a rare inflammatory disease called Takayasu arteritis.

11 Dec 2020

Lupus patients receiving prophylactic therapy are at high risk for adverse reactions

New research shows that adults with systemic lupus erythematosus, who receive trimethoprim-sulfamethoxazole (TMP-SMX), a prophylactic therapy to help prevent pneumocystis pneumonia, are at high risk for adverse reactions to the drug, particularly if they are also positive for anti-Smith (anti-Sm) antibodies.

6 Nov 2020

New study launched to find impact of vasculitis on employment, income

The Vasculitis Patient-Powered Research Network and the Vasculitis Clinical Research Consortium launched a study entitled "Impact of vasculitis on employment and income" or "VascWork." The purpose of this study is to learn about the impact of vasculitis on employment and income in patients with different systemic vasculitides.

12 Aug 2015

Researchers uncover genetics behind what makes some people susceptible to Takayasu arteritis

Researchers have uncovered the genetics behind what makes some people susceptible to Takayasu arteritis, a debilitating disease that can lead to poor circulation, easy tiredness in the legs and arms, organ damage and stroke.

30 Jul 2013

Takayasu Arteritis News and Research

RINVOQ® (upadacitinib) Approved by European Commission as an Oral Treatment for Adults with Active Non-Radiographic Axial Spondyloarthritis

Potential new diagnostic marker for ulcerative colitis discovered

Three new guidelines released for treatment and management of systemic vasculitis

Study uncovers genetic risks of Takayasu arteritis

Lupus patients receiving prophylactic therapy are at high risk for adverse reactions

New study launched to find impact of vasculitis on employment, income

Researchers uncover genetics behind what makes some people susceptible to Takayasu arteritis

Innovations in baculovirus–insect cell expression systems

Compound Management and its Crucial Role in Early Pharmaceutical Research

Natural products: the next frontier in drug discovery

Latest News